

**File No. P.17019/01/2018-PvPI****Dated: June 22, 2023****Monthly Drug Safety Alert**

The preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database revealed that the following suspected drug is associated with the ADR as given below.

**Table**

S. No.	Suspected Drug	Indication	Adverse Drug Reaction
1	Teneligliptin	For the treatment of Type-2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise.	Bullous Pemphigoid

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “ADR PvPI” and PvPI Helpline No. **1800-180-3024**.